dc.contributor.author | Florin, Esther | de |
dc.contributor.author | Koschmieder, Kim C. | de |
dc.contributor.author | Schnitzler, Alfons | de |
dc.contributor.author | Becker, Susanne | de |
dc.date.accessioned | 2025-03-17T12:43:30Z | |
dc.date.available | 2025-03-17T12:43:30Z | |
dc.date.issued | 2020 | de |
dc.identifier.issn | 1531-8257 | de |
dc.identifier.uri | https://www.ssoar.info/ssoar/handle/document/100813 | |
dc.description.abstract | Background: Of patients with Parkinson's disease (PD), 30% to 85% report pain. However, mechanisms underlying this pain remain unclear. In line with known neuroanatomical impairments, we hypothesized that pain in PD is caused by alterations in emotional-motivational as opposed to sensory-discriminative pain processing and that dopamine recovers the capacity for endogenous emotional-motivational pain modulation in patients with PD. Methods: A total of 20 patients with PD played a random reward paradigm with painful heat stimuli in addition to assessments of pain sensitivity once with and once without levodopa. Results: Levodopa increased endogenous pain inhibition in terms of perceived pain intensity and un/pleasantness compared with a medication off state. Higher clinical pain was associated with higher increases in pain inhibition. Levodopa did not affect heat pain threshold, tolerance, or temporal summation. Conclusion: Patients with PD seem to be predominately impaired in emotional-motivational as opposed to sensory-discriminative pain processing. A differential understanding of pain in PD is urgently needed because effective treatment strategies are lacking. | de |
dc.language | en | de |
dc.subject.ddc | Medizin und Gesundheit | de |
dc.subject.ddc | Medicine and health | en |
dc.subject.other | Parkinson’s disease; endogenous pain modulation; dopamine; emotional-motivational pain processing; medial pain system; Deutsche Version der Positive and Negative Affect Schedule PANAS (GESIS Panel) (ZIS 242) | de |
dc.title | Recovery of Impaired Endogenous Pain Modulation by Dopaminergic Medication in Parkinson's Disease | de |
dc.description.review | begutachtet (peer reviewed) | de |
dc.description.review | peer reviewed | en |
dc.source.journal | Movement Disorders | |
dc.source.volume | 35 | de |
dc.publisher.country | USA | de |
dc.source.issue | 12 | de |
dc.subject.classoz | Medizin, Sozialmedizin | de |
dc.subject.classoz | Medicine, Social Medicine | en |
dc.subject.thesoz | Schmerz | de |
dc.subject.thesoz | pain | en |
dc.subject.thesoz | Krankheit | de |
dc.subject.thesoz | illness | en |
dc.subject.thesoz | Medikation | de |
dc.subject.thesoz | medication | en |
dc.subject.thesoz | Patient | de |
dc.subject.thesoz | patient | en |
dc.identifier.urn | urn:nbn:de:0168-ssoar-100813-8 | |
dc.rights.licence | Creative Commons - Namensnennung 4.0 | de |
dc.rights.licence | Creative Commons - Attribution 4.0 | en |
ssoar.contributor.institution | FDB | de |
internal.status | formal und inhaltlich fertig erschlossen | de |
internal.identifier.thesoz | 10057264 | |
internal.identifier.thesoz | 10035075 | |
internal.identifier.thesoz | 10036780 | |
internal.identifier.thesoz | 10049928 | |
dc.type.stock | article | de |
dc.type.document | Zeitschriftenartikel | de |
dc.type.document | journal article | en |
dc.source.pageinfo | 2338-2343 | de |
internal.identifier.classoz | 50100 | |
internal.identifier.journal | 3317 | |
internal.identifier.document | 32 | |
internal.identifier.ddc | 610 | |
dc.identifier.doi | https://doi.org/10.1002/mds.28241 | de |
dc.description.pubstatus | Veröffentlichungsversion | de |
dc.description.pubstatus | Published Version | en |
internal.identifier.licence | 16 | |
internal.identifier.pubstatus | 1 | |
internal.identifier.review | 1 | |
internal.pdf.valid | false | |
internal.pdf.wellformed | true | |
internal.pdf.encrypted | false | |